Compare · FPRX vs TLC
FPRX vs TLC
Side-by-side comparison of Five Prime Therapeutics, Inc. (FPRX) and Taiwan Liposome Company, Ltd. (TLC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FPRX and TLC operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- TLC carries a market cap of $292.2M.
- TLC has more recent analyst coverage (2 ratings vs 0 for FPRX).
- Company
- Five Prime Therapeutics, Inc.
- Taiwan Liposome Company, Ltd.
- Price
- -
- $6.94+0.00%
- Market cap
- -
- $292.2M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2013
- 2018
- News (4w)
- 0
- 0
- Recent ratings
- 0
- 2
Taiwan Liposome Company, Ltd.
Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). The BioSeizer lipid formulation technology is designed to enable local sustained release and fast onset of APIs at the site of disease or injury with enhanced pharmacokinetic (PK) control by customization of lipid layers; and NanoX active drug loading technology enables the potential for reduced dosing frequency and enhanced distribution of liposome-encapsulated APIs to the desired site. Its lead product candidate is TLC599, an intraarticular injectable BioSeizer formulation of the API steroid dexamethasone sodium phosphate (DSP), which is in Phase III clinical trial for the treatment of knee osteoarthritis pain. The company's product candidates also comprise TLC590, a non-opioid BioSeizer formulation of the API ropivacaine that has completed Phase II clinical trial to treat post-surgical pain; TLC399, a multilamellar and multivesicular BioSeizer formulation of DSP, which is in Phase II clinical trial for ophthalmology indications; TLC178, an API that is in Phase I/II dose escalation trial to treat rhabdomyosarcoma; and TLC19 that is in Phase I clinical trial to treat COVID-19.Taiwan Liposome Company, Ltd. was founded in 1997 and is headquartered in Taipei, Taiwan.
Latest FPRX
- Apexigen Announces Appointment of Francis Sarena as Chief Operating Officer
- SEC Form SC 13G/A filed by Five Prime Therapeutics, Inc. (Amendment)
- SEC Form 15-12B filed by Five Prime Therapeutics, Inc.
- SEC Form EFFECT filed by Five Prime Therapeutics, Inc.
- SEC Form 4: Sarena Francis Willard received a gift of 2,385 units of Common Stock, was granted 66,000 units of Common Stock, disposed of $6,530,414 worth of Common Stock back to the company (171,853 units at $38.00) and gifted 20,459 units of Common Stock, decreasing direct ownership by 100% to 0 units to satisfy withholding obligation
- SEC Form 4: Smith David V was granted 66,000 units of Common Stock and disposed of $5,279,986 worth of Common Stock back to the company (138,947 units at $38.00) , decreasing direct ownership by 100% to 0 units to satisfy tax liability
- SEC Form 4: Collins Helen Louise disposed of $5,150,786 worth of Common Stock back to the company (135,547 units at $38.00) , gifted 8,085 units of Common Stock and was granted 66,000 units of Common Stock, decreasing direct ownership by 100% to 0 units to satisfy tax liability
- SEC Form 4: White David disposed of $1,270,074 worth of Common Stock back to the company (33,423 units at $38.00) , decreasing direct ownership by 100% to 0 units (tax withholding)
- SEC Form 4: RINGO WILLIAM R gifted 10,000 units of Common Stock, decreasing direct ownership by 100% to 0 units
- SEC Form 4: BERGER FRANKLIN M disposed of $190,000 worth of Common Stock back to the company (5,000 units at $38.00) , decreasing direct ownership by 100% to 0 units to satisfy tax liability
Latest TLC
- TLC Announces TLC599 Agreement with Endo
- TLC BioSciences Announces Publication of TLC599 Phase II Results in Arthritis Research & Therapy
- SEC Form SC 13D/A filed by Taiwan Liposome Company, Ltd. (Amendment)
- SEC Form SC 13D/A filed by Taiwan Liposome Company, Ltd. (Amendment)
- SEC Form SC 13D/A filed by Taiwan Liposome Company, Ltd. (Amendment)
- SEC Form CB/A filed by Taiwan Liposome Company, Ltd. (Amendment)
- SEC Form CB/A filed by Taiwan Liposome Company, Ltd. (Amendment)
- SEC Form 6-K filed by Taiwan Liposome Company, Ltd.
- SEC Form 25 filed by Taiwan Liposome Company, Ltd.
- SEC Form CB/A filed by Taiwan Liposome Company, Ltd. (Amendment)